A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years — a move expected to give millions access to the breakthrough treatment and potentially bring the world closer to ending the HIV/Aids epidemic. The drug, called Lenacapavir and administered by injection, is due to be rolled out as early as the end of this year, at a cost of $28,000 (£20,000) per person annually.
However, Wednesday's announcement promises to slash that price to just $40 — around 0.1% of the original cost. The lower-cost version will be rolled out in 2027 across 120 low- and middle-income countries.
Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral drugs was brokered by former US President Bill Clinton and involves partnerships with various foundations, making it a significant step towards combating the HIV epidemic. Lenacapavir is recommended by the WHO and is proven to provide six months of protection against HIV infection with just two injections a year, making it a potentially revolutionary alternative to daily pills. It is expected to replace the current preventative drug known as PrEP (pre-exposure prophylaxis), which is often stigmatized and difficult for users to manage.
This initiative could significantly reduce new infections, particularly among vulnerable populations, with research suggesting that even a 4% uptake could prevent up to 20% of new HIV cases. With over 40 million people currently living with HIV globally, this new agreement offers hope to those in dire need of effective and affordable treatment.
However, Wednesday's announcement promises to slash that price to just $40 — around 0.1% of the original cost. The lower-cost version will be rolled out in 2027 across 120 low- and middle-income countries.
Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral drugs was brokered by former US President Bill Clinton and involves partnerships with various foundations, making it a significant step towards combating the HIV epidemic. Lenacapavir is recommended by the WHO and is proven to provide six months of protection against HIV infection with just two injections a year, making it a potentially revolutionary alternative to daily pills. It is expected to replace the current preventative drug known as PrEP (pre-exposure prophylaxis), which is often stigmatized and difficult for users to manage.
This initiative could significantly reduce new infections, particularly among vulnerable populations, with research suggesting that even a 4% uptake could prevent up to 20% of new HIV cases. With over 40 million people currently living with HIV globally, this new agreement offers hope to those in dire need of effective and affordable treatment.
